Yahoo
NYSE - Nasdaq Real Time Price USD

Pfizer Inc. (PFE)

29.45 -0.35 (-1.17%)
At close: 4:02:59 PM EDT
29.45 0.00 (0.00%)
After hours: 4:39:33 PM EDT
Trade Pfizer on Coinbase
Dividend
PFE announced a cash dividend of $0.43 with an ex-date of Nov. 6, 2026

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Dr. Albert Bourla D.V.M., Ph.D.
Chairman of the Board & CEO 9.14M 1.64M 1962
Dr. Chris Boshoff FMedSci, M.D., Ph.D.
Chief Scientific Officer and President of Research & Development 5.2M 24.8k 1964
Mr. Douglas M. Lankler
Executive VP & Chief Legal Officer 4.62M 503.28k 1966
Mr. Aamir Malik
Executive VP & Chief U.S. Commercial Officer 4.9M -- 1976
Ms. Cecile Guegan
Interim CFO & Executive VP -- -- 1971
Ms. Jennifer B. Damico
Senior VP, Controller & Principal Accounting Officer -- -- 1969
Mr. Dennis P. Hancock
Executive VP & Chief Information Officer -- -- --
Ms. Francesca M. DeMartino
Chief Investor Relations Officer -- -- --
Ms. Payal Sahni Becher
Chief People Experience Officer & Executive VP -- -- 1975
Dr. Michael S. Vincent M.D., Ph.D.
Senior VP and Chief Scientific Officer of Inflammation & Immunology -- -- --

Pfizer Inc.

66 Hudson Boulevard East
New York, NY 10001-2192
United States
212 733 2323 https://www.pfizer.com
Sector: 
Healthcare
Full Time Employees: 
75,000

Description

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Corporate Governance

Pfizer Inc.’s ISS Governance QualityScore as of October 1, 2026 is 7. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 1; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 3, 2026 at 12:30 PM UTC

Pfizer Inc. Earnings Date

November 6, 2026 at 12:00 AM UTC

Ex-Dividend Date

December 7, 2026 at 12:00 AM UTC

Dividend Date

Recent Events

August 31, 2026 at 12:00 AM UTC

N-PX: Annual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PX

August 4, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 18, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 16, 2026 at 12:00 AM UTC

11-K: Annual report of employee stock purchase

May 5, 2026 at 12:00 AM UTC

S-8: Offering Registrations

April 27, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 12, 2026 at 12:00 AM UTC

ARS: Annual Report to Shareholders

February 26, 2026 at 12:00 AM UTC

10-K: Periodic Financial Reports

February 3, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

December 16, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: